Inventiva SA
NASDAQ:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
NASDAQ:IVA
Watchlist
Price: 6.83 USD -0.58%
Market Cap: $357.7m

Operating Margin

-719.9%
Current
Declining
by 11.2%
vs 3-y average of -708.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-719.9%
=
Operating Income
€-98m
/
Revenue
€13.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-719.9%
=
Operating Income
$-98m
/
Revenue
€13.6m

Peer Comparison

Country Company Market Cap Operating
Margin
FR
Inventiva SA
PAR:IVA
1B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in France
Percentile
5th
Based on 2 333 companies
5th percentile
-719.9%
Low
-17 526.7% — 1.3%
Typical Range
1.3% — 11.5%
High
11.5% — 89 700%
Distribution Statistics
France
Min -17 526.7%
30th Percentile 1.3%
Median 6.1%
70th Percentile 11.5%
Max 89 700%

Inventiva SA
Glance View

Market Cap
357.7m USD
Industry
Biotechnology

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

IVA Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-719.9%
=
Operating Income
€-98m
/
Revenue
€13.6m
What is Inventiva SA's current Operating Margin?

The current Operating Margin for Inventiva SA is -719.9%, which is below its 3-year median of -708.7%.

How has Operating Margin changed over time?

Over the last 3 years, Inventiva SA’s Operating Margin has increased from -1 498.8% to -719.9%. During this period, it reached a low of -1 498.8% on May 30, 2022 and a high of -466.8% on Dec 31, 2022.

Back to Top